

PeriTec™

Peritech Biosciences, Ltd.

Management:

Don Gustavson, CEO and Founder.
Timur P. Sarac, MD, President and Founder.
Nancy Rubin, CFO and Founder.

Advisory Board:

Chris Zarins, MD, Professor of Vascular Surgery, Stanford University.
Frank Veith, MD, Professor of Vascular Surgery, New York University.
Mel Shatz, CEO, Crux Biomedical.

Board of Directors:

Don Gustavson.
Timur P. Sarac, MD.
Michael Kennedy, President, Kennedy Group.
Joe Znidarsic, VP/General Counsel, Cleveland Indians.
Chris Coburn, CEO, CCFI.

Industry:

Medical Device, Peripheral Stent.

Intellectual Property:

- 3 US patents issued.
- 4 pending.
- All international filed.

Law Firms:

Tarolli, Sundheim, Covell & Tummino LLP.
Thompson Hine LLP.

Current Investors:

Angel Investors.

Stage:

Technology:

Device:

Application:

Customers:


Funding:

Retail Price:

Exit:

Market:

50 in Man.
Medical Device.
Tissue Lined Stent.
Leg Blockage;
Vascular Surgeons, Radiologists
and Cardiologists.
Angel Investors \$6M.
Grants \$2M.
\$2,500 per stent.
Acquisition or IPO.
\$6B.



10 years ago, a patient was having a ruptured abdominal aneurysm repaired when the surgeon noted that the blood was clotting to everything except the peritoneal tissue. That surgeon was Dr. Timur P. Sarac, and the revelation that he had at that time sparked the idea to create an endovascular stent graft that is lined with bovine peritoneal tissue.

Existing Procedure (Bare-Metal and Covered Stent Grafts): Bare-metal stents are used to treat stenosis of peripheral arteries. They are implanted during a minimally invasive, endovascular procedure through a very small incision.

Limitations of Bare-Metal and Covered Stent Grafts: These stents often clot off as excessive scarring forms on the exposed metal mesh or wire or stent graft material. In these cases the patient may require re-intervention via another endovascular surgery or even an invasive surgery.

PeriTec Biosciences Description: A medical device company creating stents lined with bovine peritoneal tissue. PeriTec's stents do not cause the same ill-effects that bare-metal and covered stent grafts do. This greatly reduces the likelihood of another interventional procedure being needed.

Business Model Summary: Design and patent tissue-lined stents that will dramatically impact the way occluded peripheral blood vessels are treated.

Problems with existing procedure:

1. Restenosis or scarring of the blood vessels: The body's reaction to the foreign material causes scarring which can eventually lead to stent occlusion.
2. Stent fractures: A break in the stent material can cause stent occlusion.

PeriTec's Solution:

1. A hybrid solution which uses biology in combination with stents in a way which vastly reduces the likelihood of the adverse reactions that accompany other stents.
2. Optimal blood flow is assured by specifically designed stents.

Applications:

PeriTec's innovative tissue lining is a platform technology. This means that it can be adapted to many different situations with virtually infinite possible applications. Some of these possibilities include:

1. **Peripheral Ischemia**—an issue which occurs when there is reduced bloodflow to the limbs; the stent is used to remedy the situation.
2. **AV Fistula Occlusion**—when the connection between an artery and a vein which is used for dialysis treatment closes off the stent is used to restore blood flow.
3. **TIPS Procedure**—the stent is placed in a hepatic blood vessel in order to divert blood flow.
4. **Coronary Artery Saphenous Vein Graft**—when the blood vessel used in a heart bypass clots off the stent is used to reopen it.
5. **Iliac Artery**—the stent is used to treat a lesion of the iliac arteries.
6. **Tibial Artery**—stenosis of the tibial arteries is treatable with the stent.
7. **Aortic Valve**—it is possible to treat incompetent aortic valves with the stent.
8. **Carotid Arteries**—the stent is used to reopen stenosed carotid arteries.

Secret Sauce:

PeriTec Biosciences is making remarkable advancements in endovascular surgery technology. The concept behind these pioneering new stents is that the tissue which lines them is able to heal into the excluded vessel just as the patient's own tissue would, greatly reducing the possibility of the patient having restenosis or clotting at the lesion site.

Competition:

- Gore, Viabahn Endoprosthesis.
- Medtronic, "The Complete."
- Bard, LifeStent
- Abbott, Absolute Stent
- Cordis, S.M.A.R.T. Stent
- EV3, Protégé.